Medifast, Inc, through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products. It offers bars, bites, pretzels, puffs, oatmeal and cereal crunch products, drinks, hearty choices, pancakes, puddings, soft serves, shakes, smoothies, soft bakes, and soups under the Medifast, OPTAVIA, Thrive by Medifast, Optimal Health by OPTAVIA, Flavors of Home, and Essential 1 brands.
Read More…
Industry, Sector and Symbol
Industry Miscellaneous food preparations & kindred products
Sub-IndustryPersonal Products
SectorConsumer Staples
Phone410-581-8042
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$501 million
Profitability
Miscellaneous
Employees420
Next Earnings Date2/25/2020 (Estimated)
OptionableOptionable
Medifast (NYSE:MED) Frequently Asked Questions
What is Medifast's stock symbol?
Medifast trades on the New York Stock Exchange (NYSE) under the ticker symbol "MED."
How often does Medifast pay dividends? What is the dividend yield for Medifast?
Medifast announced a quarterly dividend on Thursday, December 5th. Shareholders of record on Friday, December 27th will be paid a dividend of $1.13 per share on Thursday, February 6th. This represents a $4.52 dividend on an annualized basis and a yield of 4.43%. The ex-dividend date of this dividend is Thursday, December 26th. This is a positive change from Medifast's previous quarterly dividend of $0.75. View Medifast's Dividend History.
How were Medifast's earnings last quarter?
Medifast Inc (NYSE:MED) posted its earnings results on Thursday, November, 7th. The specialty retailer reported $1.32 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $1.33 by $0.01. The specialty retailer had revenue of $190.10 million for the quarter, compared to analyst estimates of $194.70 million. Medifast had a net margin of 10.70% and a return on equity of 62.93%. Medifast's revenue for the quarter was up 36.5% compared to the same quarter last year. During the same quarter last year, the firm earned $1.14 EPS. View Medifast's Earnings History.
When is Medifast's next earnings date?
What guidance has Medifast issued on next quarter's earnings?
Medifast updated its FY 2019
After-Hours earnings guidance on Monday, November, 25th. The company provided earnings per share guidance of $5.80-5.90 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.83. The company issued revenue guidance of $$700-710 million, compared to the consensus revenue estimate of $$750.45 million.
What price target have analysts set for MED?
4 equities research analysts have issued 1 year price objectives for Medifast's shares. Their forecasts range from $74.00 to $216.00. On average, they expect Medifast's stock price to reach $140.00 in the next year. This suggests a possible upside of 37.1% from the stock's current price. View Analyst Price Targets for Medifast.
What is the consensus analysts' recommendation for Medifast?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Medifast.
Has Medifast been receiving favorable news coverage?
News headlines about MED stock have trended positive recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Medifast earned a news impact score of 3.0 on InfoTrie's scale. They also gave news headlines about the specialty retailer a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Medifast.
Are investors shorting Medifast?
Medifast saw a drop in short interest in the month of January. As of January 15th, there was short interest totalling 4,110,000 shares, a drop of 8.9% from the December 31st total of 4,510,000 shares. Based on an average daily trading volume, of 408,800 shares, the days-to-cover ratio is presently 10.1 days. Currently, 37.1% of the shares of the stock are short sold. View Medifast's Current Options Chain.
Who are some of Medifast's key competitors?
What other stocks do shareholders of Medifast own?
Who are Medifast's key executives?
Medifast's management team includes the folowing people:
- Mr. Daniel R. Chard, CEO & Director (Age 54)
- Mr. Timothy G. Robinson CPA, CPA, Chief Financial Officer (Age 57)
- Mr. William Baker IV, Exec. VP of Information Technology (Age 47)
- Mr. Nicholas Johnson, Exec. VP of Coach Success Market Pres of OPTAVIA USA (Age 39)
- Mr. Jason L. Groves, Exec. VP, Gen. Counsel & Corp. Sec. (Age 48)
Who are Medifast's major shareholders?
Medifast's stock is owned by a number of of institutional and retail investors. Top institutional investors include Ingalls & Snyder LLC (0.54%), Winmill & CO. Inc. (0.34%), California Public Employees Retirement System (0.30%), Chickasaw Capital Management LLC (0.28%), Goodwin Daniel L (0.22%) and New York State Teachers Retirement System (0.14%). Company insiders that own Medifast stock include Carl E Sassano, Charles P Connolly, Constance J Hallquist, Daniel R Chard, Michael A Hoer, Michael C Macdonald and Scott Schlackman. View Institutional Ownership Trends for Medifast.
Which major investors are selling Medifast stock?
MED stock was sold by a variety of institutional investors in the last quarter, including Arizona State Retirement System, Virginia Retirement Systems ET AL, California Public Employees Retirement System, Chickasaw Capital Management LLC, Louisiana State Employees Retirement System and State of Alaska Department of Revenue. Company insiders that have sold Medifast company stock in the last year include Carl E Sassano and Scott Schlackman. View Insider Buying and Selling for Medifast.
Which major investors are buying Medifast stock?
MED stock was purchased by a variety of institutional investors in the last quarter, including Winmill & CO. Inc., Goodwin Daniel L, Eqis Capital Management Inc., Ingalls & Snyder LLC, Nisa Investment Advisors LLC, New York State Teachers Retirement System, FormulaFolio Investments LLC and Hollencrest Capital Management. Company insiders that have bought Medifast stock in the last two years include Daniel R Chard and Michael A Hoer. View Insider Buying and Selling for Medifast.
How do I buy shares of Medifast?
Shares of MED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Medifast's stock price today?
One share of MED stock can currently be purchased for approximately $102.08.
How big of a company is Medifast?
Medifast has a market capitalization of $1.19 billion and generates $501 million in revenue each year. The specialty retailer earns $55.79 million in net income (profit) each year or $4.62 on an earnings per share basis. Medifast employs 420 workers across the globe.View Additional Information About Medifast.
What is Medifast's official website?
How can I contact Medifast?
Medifast's mailing address is 100 International Drive, Baltimore MD, 21202. The specialty retailer can be reached via phone at 410-581-8042 or via email at [email protected]
MarketBeat Community Rating for Medifast (NYSE MED)
MarketBeat's community ratings are surveys of what our community members think about Medifast and other stocks. Vote "Outperform" if you believe MED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MED will underperform the S&P 500 over the long term. You may vote once every thirty days.
